Treatment of bullous pemphigoid in Chinese patients with Tripterygium wilfordii Hook F

Tripterygium wilfordii Hook F (TwHF) is a traditional Chinese herb used in many medicinal applications, but the treatment of bullous pemphigoid (BP) with TwHF has never been reported. The aim of this study was to evaluate the efficacy and safety of TwHF in BP patients. A retrospective study was performed from January 2015 to September 2019 in the Department of Dermatology, Peking Union Medical College Hospital. A total of 10 patients with mild to moderate BP and treated with TwHF were enrolled in the study with 10 mild or moderate BP patients treated with systemic glucocorticoid randomly selected as controls. In the TwHF group, a major response was seen in seven patients, a minor response in one and no response was seen in two patients. In the glucocorticoid group, a major response was seen in nine patients and a minor response in one patient. Two patients experienced treatment failure. The time to disease control in the TwHF group (34 ± 11 days) was longer as compared to the glucocorticoid group (18 ± 8 days, P < .05). Ten patients relapsed during the follow‐up period. The adverse events in the TwHF group were lower than those in the glucocorticoid group (13 vs 19). Low‐dose TwHF may be effective and safe for treating mild and moderate BP.

[1]  K. Johnell,et al.  Low-dose methotrexate use and safety for older patients with bullous pemphigoid and impaired renal function: a cohort study. , 2020, Journal of the American Academy of Dermatology.

[2]  L. Xiaowei,et al.  Evaluation of the efficacy and safety of TWHF in diabetic nephropathy patients with overt proteinuria and normal eGFR. , 2019, Journal of the Formosan Medical Association = Taiwan yi zhi.

[3]  H. Shimizu,et al.  Regulatory T‐cell dysfunction induces autoantibodies to bullous pemphigoid antigens in mice and human subjects , 2018, The Journal of allergy and clinical immunology.

[4]  B. Li,et al.  Efficacy and safety of Tripterygium wilfordii hook F for chronic urticaria: a systematic review and meta-analysis , 2018, BMC Complementary and Alternative Medicine.

[5]  Xin Chen,et al.  Effects of Tripterygium wilfordii Induction Therapy to IgA Nephropathy Patients with Heavy Proteinuria. , 2017, Biological & pharmaceutical bulletin.

[6]  Xiaojun Zhang,et al.  Protective Effect of 18β-Glycyrrhetinic Acid against Triptolide-Induced Hepatotoxicity in Rats , 2017, Evidence-based complementary and alternative medicine : eCAM.

[7]  Xiaoyan Xiao,et al.  Huang Gan Formula Eliminates the Oxidative Stress Effects of Advanced Oxidation Protein Products on the Divergent Regulation of the Expression of AGEs Receptors via the JAK2/STAT3 Pathway , 2017, Evidence-based complementary and alternative medicine : eCAM.

[8]  Xiaoyan Wu,et al.  Tripterygium wilfordii polyglycosidium ameliorates pouchitis induced by dextran sulfate sodium in rats , 2017, International immunopharmacology.

[9]  T. Ruzicka,et al.  Bullous pemphigoid. , 2017, Autoimmunity reviews.

[10]  L. Ye,et al.  Effect of Tripterygium Wilfordii Polyglycoside on Experimental Prostatitis Caused by Ureaplasma Urealyticum in Rats , 2016, Medical science monitor : international medical journal of experimental and clinical research.

[11]  Y. Ma,et al.  Effects of Tripterygium wilfordii glycosides on regulatory T cells and Th17 in an IgA nephropathy rat model. , 2015, Genetics and molecular research : GMR.

[12]  D. Zillikens,et al.  S2k guidelines for the treatment of pemphigus vulgaris/foliaceus and bullous pemphigoid , 2015, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[13]  D. Zillikens,et al.  Management of bullous pemphigoid: the European Dermatology Forum consensus in collaboration with the European Academy of Dermatology and Venereology , 2015, The British journal of dermatology.

[14]  P. Lipsky,et al.  Comparison of Tripterygium wilfordii Hook F with methotrexate in the treatment of active rheumatoid arthritis (TRIFRA): a randomised, controlled clinical trial , 2014, Annals of the rheumatic diseases.

[15]  Baoxi Wang,et al.  Treatment of coexisting bullous pemphigoid and psoriasis with triptergium wilfordii. , 2014, Chinese medical journal.

[16]  R. Wolf,et al.  Bullous pemphigoid: etiology, pathogenesis, and inducing factors: facts and controversies. , 2013, Clinics in dermatology.

[17]  Yunzhao Zhao,et al.  Prevention of postoperative recurrence of Crohn’s disease: Tripterygium wilfordii polyglycoside versus mesalazine , 2013, The Journal of international medical research.

[18]  M. Mustapa,et al.  British Association of Dermatologists’ guidelines for the management of bullous pemphigoid 2012 , 2012, The British journal of dermatology.

[19]  Yonglong Yan,et al.  Triptolide regulates T cell-mediated immunity via induction of CD11c(low) dendritic cell differentiation. , 2012, Food and Chemical Toxicology.

[20]  H. Shimizu,et al.  Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts. , 2012, Journal of the American Academy of Dermatology.